Stereotactic Re-irradiation of Local Recurrences of Prostate Cancer After Radiotherapy

The goal of this clinical study is to evaluate the toxicity and efficacy of re-irradiation using focal stereotactic body radiotherapy (SBRT) in patients with local recurrence of prostate cancer after definitive or post-operative radiotherapy. The main question is the tolerance of such treatment, concerning the incidence of Grade ≥ 2 and Grade ≥ 3 GU and GI toxicity. Also the efficacy of SBRT will be measured in terms of Biochemical Control with other secondary endpoints which include: Biochemical Response, Biochemical Failure-Free Survival, Metastases-Free Survival, Relapse-Free Survial, Loca

Trial Details

NCT ID

NCT06201078

Phase

PHASE2

Sponsor

Maria Sklodowska-Curie National Research Institute of Oncology

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

• Stereotactic Body Radiotherapy

Locations (sample)

• Gliwice, Poland|50.29761,18.67658

Key Eligibility Criteria

• Local recurrence of prostate cancer after definitive radiotherapy
• biopsy proven or/and
• Consistent MRI and PET-PSMA results and PSA growth dynamics
• Time since primary radiotherapy - at least 2 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →